Patents Assigned to Takeda
  • Roflumilast for the treatment of diabetes mellitus type 2
    Patent number: 8541456
    Abstract: The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: September 24, 2013
    Assignee: Takeda GmbH
    Inventors: Hans-Peter Kley, Guido Hanauer, Daniela Hauser, Beate Schmidt, Dirk Bredenbröker, Wilhelm Wurst, Jörg Kemkowski
  • FUSED HETEROAROMATIC PYRROLIDINONES
    Publication number: 20130245031
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
    Type: Application
    Filed: May 2, 2013
    Publication date: September 19, 2013
    Applicant: Takeda Phamaceutical Company Limited
    Inventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Christopher Smith, Massashi Takahashi, Qing Dong, Victoria Feher, Zhi Nie
  • ORALLY DISINTEGRATING TABLET
    Publication number: 20130243859
    Abstract: The present invention relates to a multi-layer orally disintegrating tablet having (1) an enteric fine granule-containing layer containing a proton pump inhibitor and (2) an acetylsalicylic acid-containing layer, which shows high stability of the active ingredients (proton pump inhibitor, aspirin) and expresses the pharmacological effects of the active ingredients stably and rapidly after administration.
    Type: Application
    Filed: December 2, 2011
    Publication date: September 19, 2013
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yasushi Mima, Tetsuya Kawano, Yumiko Ishii
  • Process for the preparation of roflumilast
    Patent number: 8536206
    Abstract: The invention relates to novel processes for the preparation of high-purity roflumilast.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: September 17, 2013
    Assignee: Takeda GmbH
    Inventors: Bernhard Kohl, Bernd Mueller, Walter Palosch
  • Organ-specific gene, method for identifying the same and use thereof
    Patent number: 8535880
    Abstract: The present invention provides a method of extracting an organ- or tissue-specific highly expressed gene, including: (1) a step for measuring expression level of a specified gene group for each organ or tissue in 2 or more individuals, (2) a step for acquiring (a) a minimum value of expression levels in a particular organ or tissue in all individuals, and (b) a maximum value of expression levels in other organs and tissues in all individuals, for each gene, and (3) a step for extracting the gene as a gene highly expressed specifically in the particular organ or tissue if the above-described (a)/(b) ratio is larger than 1. By the present invention, truly organ- or tissue-specific genes are extracted.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: September 17, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Saku Miyamoto, Kenji Takami, Akira Horinouchi
  • Glucokinase activators
    Patent number: 8530499
    Abstract: Compounds of the following formula are provided for use with glucokinase: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: September 10, 2013
    Assignee: Takeda San Diego, Inc.
    Inventors: Zacharia Cheruvallath, Jun Feng, Prasuna Guntupalli, Stephen L. Gwaltney, Joanne Miura, Mark Sabat, Mingnam Tang, Haxia Wang
  • PROCESS FOR MAKING (R) -3-(2,3-DIHYDROXYPROPYL)-6-FLUORO-5-(2-FLOURO-4-IODOPHENYLAMINO)-8-METHYLPYRIDO[2,3-d]PYRIMIDINE-4,7(3H,8H)-DIONE AND INTERMEDIATES THEREOF
    Publication number: 20130225813
    Abstract: The present invention relates generally intermediates for making (R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione.
    Type: Application
    Filed: March 20, 2013
    Publication date: August 29, 2013
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: David Paul Provencal
  • Remedies for sex hormone dependent disease
    Patent number: 8518890
    Abstract: A combination agent containing an LHRH receptor agonist or antagonist and an androgen receptor agonist, which is useful as an agent for the prophylaxis or treatment of hormone-dependent diseases and the like, is provided.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: August 27, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahito Hara, Masami Kusaka
  • Colchicine solid complex; methods of making; and methods of use thereof
    Patent number: 8519002
    Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: August 27, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Tong Sun, David Jonaitis, Stephan D. Parent
  • Pyridazinone compounds
    Patent number: 8513251
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: August 20, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiko Taniguchi, Jun Kunitomo
  • METHOD OF PRODUCING PANCREATIC HORMONE-PRODUCING CELLS
    Publication number: 20130210060
    Abstract: Disclosed is a production method of pancreatic hormone-producing cells in a form that mimics the pancreatogenesis, the method comprising subjecting stem cells to the following steps: (1) cultivating stem cells in a medium containing a Rho kinase inhibitor, (2) cultivating the cells obtained in (1) in a medium containing a GSK3 inhibitor, (3) cultivating the cells obtained in (2) in a medium containing GSK3 inhibitor and an activator of activin receptor-like kinase-4,7, (4) forming a cell mass from the cells obtained in (3), and cultivating the cell mass in a suspension state in a medium, (5) cultivating the cells obtained in (4) in a medium containing a retinoic acid receptor agonist, an inhibitor of AMP-activated protein kinase and/or activin receptor-like kinase-2,3,6, an inhibitor of activin receptor-like kinase-4,5,7 and a cell growth factor, and (6) cultivating the cells obtained in (5).
    Type: Application
    Filed: August 8, 2011
    Publication date: August 15, 2013
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masaki Hosoya, Masanobu Shoji
  • SUSTAINED-RELEASE FORMULATION
    Publication number: 20130210742
    Abstract: The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic polymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably releases compound (I) or a salt thereof over a long period of time and exerts medicinal effects of compound (I) or a salt thereof over a long period of time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing frequency of administration, is an excellent formulation as a clinical medicine.
    Type: Application
    Filed: June 23, 2011
    Publication date: August 15, 2013
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tomomichi Futo, Hikaru Taira, Seitaro Mizukami, Naoyuki Murata
  • APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS
    Publication number: 20130203731
    Abstract: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: March 28, 2013
    Publication date: August 8, 2013
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: TAKEDA PHARMACEUTICAL COMPANY LIMITE LIMITED
  • Bicyclic compound
    Patent number: 8501804
    Abstract: The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: August 6, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Makoto Kamata, Tohru Yamashita, Asato Kina, Michiko Amano
  • Heterocyclic compound and use thereof
    Patent number: 8501750
    Abstract: Heterocyclic compounds, pharmaceutical agent and methods thereof, having superior pharmacological action and/or physicochemical properties, which are useful for the prophylaxis or treatment of circulatory diseases such as hypertension, cardiac diseases, arteriosclerosis, renal diseases and cerebral apoplexy and/or metabolic diseases such as hyperlipidemia, obesity and diabetes and/or central nervous disorders such as cerebral infarction, and/or mental diseases such as dementia depression and depression.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: August 6, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takanobu Kuroita, Hideyuki Igawa, Hiroki Sakamoto, Kouhei Asano, Minoru Sasaki
  • Thiocolchicine derivatives, method of making and methods of use thereof
    Patent number: 8497290
    Abstract: Disclosed herein are thiocolchicine derivatives suitable for use as muscle relaxants, methods of making the derivatives, and compositions comprising the derivatives.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: July 30, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Rajesh Manchanda
  • Heterocyclic compound and use thereof
    Patent number: 8497274
    Abstract: Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: July 30, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masanori Okaniwa, Terufumi Takagi, Masaaki Hirose
  • Antibody purification method
    Patent number: 8497358
    Abstract: Provided is a purification method that purifies an antibody to a high purity, effectively removes antibody polymer (or aggregate), and improves antibody recovery rate. An antibody purification method including a step for treating a solution containing an antibody by mixed mode chromatography in the presence of an amino acid is provided.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: July 30, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Suenaga, Takeshi Hayakawa, Takuya Muramoto
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20130190291
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Application
    Filed: August 9, 2011
    Publication date: July 25, 2013
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masakuni Kori, Toshihiro Imaeda, Shinji Nakamura, Masashi Toyofuku, Eiji Honda, Yasutomi Asano, Osamu Ujikawa, Michiyo Mochizuki
  • Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
    Patent number: 8492405
    Abstract: The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like. A glucokinase activator containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: July 23, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Yasuma, Yasufumi Miyamoto